BACKGROUND: A diagnosis of malignant hyperthermia susceptibility by in vitro contraction testing can often only be performed at specialized laboratories far away from where patients live. Therefore, we have designed a protocol for genetic screening of the RYR1-cDNA and for functional testing of newly identified ryanodine receptor 1 (RYR1) gene variants in B lymphocytes isolated from peripheral blood samples drawn at local primary care centers. METHODS: B lymphocytes were isolated for the extraction of RYR1-mRNA and genomic DNA and for establishment of lymphoblastoid B cell lines in 5 patients carrying yet unclassified mutations in the RYR1. The B lymphoblastoid cell lines were used to study resting cytoplasmic calcium concentration, the peak calcium transient induced by the sarco(endo)plasmic reticulum Ca-ATPase inhibitor thapsigargin, and the dose-dependent calcium release induced by the ryanodine receptor agonist 4-chloro-m-cresol. RESULTS: It was possible to extract mRNA for cDNA synthesis and to create B lymphocyte clones from all samples. All B lymphoblastoid cell lines carrying RYR1 candidate mutations showed significantly increased resting cytoplasmic calcium levels as well as a shift to lower concentrations of 4-chloro-m-cresol inducing calcium release compared with controls. CONCLUSIONS: Peripheral blood samples are stable regarding RNA and DNA extraction and establishment of lymphoblastoid B cell lines after transportation at ambient temperature over large distances by ordinary mail. Functional tests on B cells harboring the newly identified amino acid substitutions indicate that they alter intracellular Ca 2ϩ homeostasis and are most likely causative of malignant hyperthermia. (Anesth Analg 2010;111:185-90) . §Drs. M. Vukevic and M. Broman contributed equally to the study.
I n individuals who are genetically malignant hyperthermia (MH) susceptible (MHS) (Online Mendelian Inheritance in Man [OMIM] 145600), volatile anesthetics and/or succinylcholine can induce a severe decompensation of muscle calcium homeostasis leading to a lifethreatening crisis including hyperthermia, tachycardia, coagulation disturbances, generalized muscle rigidity, oliguria, and eventually death. 1 The diagnosis of MHS is traditionally made by an in vitro contraction test (IVCT). This investigation is highly invasive, requiring an open muscle biopsy from musculus quadriceps and specialized testing equipment. 2 The clinical presentation of central core disease (CCD) (OMIM 117000) is highly variable and symptoms can vary from clinically very mild to severe congenital myopathy with hypotonia, skeletal abnormalities, and scoliosis. 3, 4 The ryanodine receptor 1 (RYR1) is encoded by the RYR1 gene located on chromosome 19q13.1. The gene comprises 159,000 base pairs that are distributed over 106 exons. The RYR1-cDNA has a length of 15,117 kb and encodes a protein monomer of 5038 amino acids. 5, 6 More than 200 sequence variants in the RYR1 gene have been identified and linked to MHS, CCD, and other neuromuscular disorders, yet the functional impact of only a minority of these amino acid substitutions has been elucidated (www.emhg.org). The vast majority of these variants have been found in individual patients and their families, and only a few recurrent variants each account for Ͻ10% of the MHS subjects. 5, 6 Ca 2ϩ is a second messenger in skeletal muscle cells. It is stored in the sarcoplasmic reticulum, an organelle whose function is intimately linked to regulating the myoplasmic Ca 2ϩ concentration, [7] [8] [9] [10] [11] and is released via a process known as excitation-contraction coupling. When the dihydropyridine receptor (DHPR), the voltage sensor on the plasmalemma, senses a change in membrane potential, it undergoes a conformational change and directly interacts with the RYR1 Ca 2ϩ channel, causing it to open. DHPR and RYR1 form highly organized structures on their respective membranes: 4 DHPR units on the transverse tubular membrane face corresponding RYR1 tetramers located on the junctional face membrane of the terminal cisternae. 12 Because Ca 2ϩ can act as a second messenger in many biological functions, its intracellular concentration is tightly regulated and maintained in a typical resting mammalian cell at about 60 to 120 nM, whereas the extracellular free Ca 2ϩ concentration is about 2 mM. 8, 9 Any alteration of Ca 2ϩ homeostasis can affect the function of cells. In muscle cells, genetic disturbances of Ca 2ϩ handling result in a variety of neuromuscular disorders such as MHS, CCD, some forms of multiminicore disease and centronuclear myopathy, and Brody disease. 4, 6, 13 Although the RYR1 is mainly expressed in striated muscle cells, it is now well established that B lymphocytes also express this calcium channel. 14, 15 The aim of this study was to develop an alternative protocol for diagnostic studies on MHS individuals by transporting blood samples instead of the patients themselves to the specialized testing center. This increases the opportunity of MHS diagnosis even if a patient's health service provider is far away from the MH laboratory. We designed a simple and practical protocol for the collection of blood samples to be drawn at the patients' local primary care centers. Three venous peripheral blood samples of 5 mL each were collected in different test tubes for mRNA and genomic DNA extraction and for establishment of B lymphoblastoid cell lines. Genetic screening and functional studies were successfully performed on these samples.
METHODS

Clinical Presentation
With Regional Ethics Committee approval, the patients participating in the study were informed by telephone and also signed a written consent to the study. All patients carried 1 candidate RYR1 mutation each: patient 1: p.Glu1058Lys, patient 2: p.Arg1679His, patient 3: p.His382Asn, patient 4: p.Lys1393Arg, and patient 5: p.Arg2508Gly. These patients are from a cohort of 15 Scandinavian MHS patients, who were screened for the RYR1 total coding region in our previous study 16 and found to carry a novel or yet unclassified sequence variant.
Details of the clinical presentation of the patients with the reported RYR1 amino acid substitutions are given in Table 1 and in Appendix 1 (see Supplemental Digital Content 1, http://links.lww.com/AA/A61).
For patients 1 to 4, the MH rank was assessed. The MH rank describes the qualitative likelihood, from 1 ϭ almost never to 6 ϭ almost certain, that an adverse anesthetic event represents MH. This clinical grading scale requires the anesthesiologist to judge whether specific clinical signs are appropriate for the patient's medical condition, anesthetic technique, or surgical procedure. 17 The MH rank scores are presented in Table 1 and in Appendix 1 (see Supplemental Digital Content 1, http://links.lww.com/AA/A61). Patient 5 has an established CCD diagnosis and his main symptoms are scoliosis and muscle weakness in the lower extremities. A microscopic histopathologic picture of his muscle tissue is shown in Figure 1 .
In Vitro Contraction Test
Patients 1 to 4 had experienced serious MH clinical reactions and thereafter were tested by IVCT and classified as MHS. The patient with CCD (patient 5) was tested by the IVCT as part of standard diagnostic investigations to establish his diagnosis and was also classified as MHS. All IVCTs were performed at the National Swedish Malignant Hyperthermia Laboratory of Lund University Hospital according to the European Malignant Hyperthermia group protocol. 2 The results of the IVCTs are presented in Table 1 and in Appendix 1 (see Supplemental Digital Content 1, http://links.lww.com/AA/A61).
Blood Sampling
The patients were provided with written information about the sampling process. Peripheral venous blood samples Maximal contractures in IVCT at the threshold concentrations of caffeine (2.0 mmol/L) and halothane (0.44 mmol/L) and the RYR1 candidate mutations are given. The MH rank describes the likelihood that the clinical adverse reaction is MH. 17 were drawn by the local family doctor in an EDTA tube, a PAXgene tube (BD, Stockholm, Sweden), and a heparin tube. The tubes were sent by normal mail without further handling or cooling to the laboratory in Wü rzburg, Germany, a distance up to 2000 km and a transportation time up to 6 days. Because PAXgene tubes are not normally available at Swedish primary care centers, they were provided to the patients.
Genetics
Total RNA was extracted from the PAXgene tubes according to the manufacturer's instructions, and genomic DNA of leukocytes was extracted from the EDTA tubes according to standard protocols. First-strand cDNA was synthesized using SuperScript™ II (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Because of the size of the RYR1-mRNA, the first cDNA strand was synthesized using 3 mixes of specific primers. The resulting first strands were then amplified in 500 to 700 base pairs overlapping fragments using a second set of primers (primer sequences are available from the authors on request). Sequencing was performed by using the BigDye 1.1 kit on an ABI 3130 XL (Applied Biosystems, Darmstadt, Germany). All cDNA sequence variants leading to amino acid substitutions were confirmed on genomic DNA from the same patient. 16, 18 Establishment of Epstein-Barr Virus Immortalized B Lymphoblastoid Cell Lines B lymphocytes were isolated from the blood collected in the heparin tubes and transformed by the Epstein-Barr virus, as previously described. 18 
Functional Tests
Changes in the intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) of the B lymphoblastoid cells from patients carrying the candidate mutations and from healthy controls were assessed as previously described 14, 18 after loading cells with the fluorescent Ca 2ϩ indicator fura-2/AM (5-M final concentration). Experiments were performed on cell populations (1.0 ϫ 10 6 cells/mL, final volume 1.5 mL) in a thermostated LS-50 Perkin-Elmer (Waltham, MA) spectrofluorimeter equipped with a magnetic stirrer. The peak increase of the Ca 2ϩ transient obtained after addition of a given concentration of 4-chloro-m-cresol on the linear part of the fura-2 calcium-sensitive curve was expressed as percentage of the peak Ca 2ϩ released by maximal concentrations (1000 M) of 4-chloro-m-cresol. To assess the size of the intracellular Ca 2ϩ stores, the area under the curve (AUC) obtained after addition of 400 nM thapsigargin, which represents the total amount of Ca 2ϩ present in the rapidly releasable intracellular Ca 2ϩ stores, was also calculated.
Statistical Analysis
Statistical analysis was performed using Student t test for paired samples or ANOVA when Ͼ2 groups were compared. The Origin computer program (Microcal Software, Northampton, MA) was used for statistical analysis and dose-response curve generation. The AUC values were calculated from the dose-response curves, whereas the 50% effective concentration (EC 50 ) and R max values were calculated from sigmoidal curve fitting of all data points. Results are expressed as mean value (Ϯsem) of n results, where n is the number of measurements. 
RESULTS
After the sampling protocol as outlined in Methods section, peripheral blood samples proved to be sufficiently stable during transportation by ordinary mail at ambient temperatures over a period of up to 6 days for RNA and DNA extraction and establishment of lymphoblastoid B cell lines. Genetic screening for the presence of RYR1 mutations 16 and calcium measurements on B lymphocytes could successfully be performed on these samples. We first examined the resting [Ca 2ϩ ] i of the B lymphocytes carrying the newly identified sequence variants and compared it with the resting [Ca 2ϩ ] i of healthy controls (Fig. 2) . All cell lines carrying a candidate mutation showed statistically significantly higher resting [Ca 2ϩ ] i compared His382Asn. E, p.Lys1393Arg. F, p.Arg2508Gly. Conditions as described in Figure 2 . The peak increase of the Ca 2ϩ transient, obtained after addition of a given concentration of 4-chloro-m-cresol on the linear part of the fura-2 calcium-sensitive curve, was expressed as percentage of the peak Ca 2ϩ released by maximal concentrations (1000 M) of 4-chloro-m-cresol. Results are expressed as mean Ϯ SEM (n ϭ 4 -9), where n indicates the number of independent measurements each performed on 1.5 ϫ 10 6 cells. Sigmoidal dose-response curves were generated using Origin software.
Functional Properties of RYR1 Mutations with cell lines from healthy controls. However, the AUC calculations of the Ca 2ϩ transient obtained after stimulating the B lymphocytes with 400 nM thapsigargin were all within the same range, irrespective of whether the cells were obtained from controls or from individuals carrying the indicated RYR1 candidate mutations (Fig. 2) . These results imply that none of the mutations affect the size of the intracellular Ca 2ϩ stores in a way that could not be compensated by the cells. Nevertheless, all the amino acid substitutions affect Ca 2ϩ homeostasis because they cause a small but significant increase in the resting Ca 2ϩ , a result that has been previously shown for B lymphocytes from individuals with the MHS phenotype. 15,19 -21 We next determined whether the newly identified mutations affect the sensitivity of Ca 2ϩ release induced by the RYR1 agonist 4-chloro-m-cresol. Figure 3A shows the typical increase in cytoplasmic [Ca 2ϩ ] i obtained in control cells after the addition of 600 M 4-chloro-m-cresol. The trace, which represents the mean change in fluorescence of 1.5 ϫ 10 6 cells, shows that addition of the RYR1 agonist is accompanied by a transient increase in the 340/380 nm fluorescent ratio, which returns to resting levels within about 10 minutes. We then constructed 4-chloro-m-cresol dose-response curves by calculating the peak Ca 2ϩ released by 4-chloro-m-cresol in a population (1.5 ϫ 10 6 cells) of fura-2-loaded lymphoblastoid B cells as a percentage of the maximal amount that could be released by 1000 M 4-chloro-m-cresol. Results are given as means Ϯ sem. The dose-response curves from the cell lines carrying each of the candidate mutations showed a significant shift to the left compared with the curves from the cell lines from healthy controls. Table 2 shows the EC 50 values for 4-chloro-m-cresol-induced Ca 2ϩ release.
DISCUSSION
In this study, we used a practical protocol to draw peripheral blood samples from MHS individuals at their local primary care centers to screen and identify RYR1 variants and to perform functional tests on the newly identified candidate mutations. Blood samples were sent by ordinary mail from different locations in Sweden to the laboratory in Wü rzburg, Germany, from September to January, which is autumn and winter in Northern Europe. Thus, the samples were not exposed to extreme heat, which could have compromised their viability. Four of the substitutions described in the present report were identified in MHS patients who had developed lifethreatening MH reactions during anesthesia (p.Glu1058Lys, p.Arg1679His, p.His382Asn, and p.Lys1393Arg). None of these substitutions have been reported in former patients. The fifth substitution (p.Arg2508Gly), occurring in the patient with CCD, has been identified before in a cohort of patients with CCD from Japan. 22 Patient 1 (p.Glu1058Lys) has shown signs of a mild muscular disease (Appendix 1, see Supplemental Digital Content 1, http://links.lww.com/AA/A61), but despite intensive investigations, a definitive diagnosis has not been established. Patients with myotonic muscle disease can especially react to succinylcholine 23 and thus one could argue the reaction she experienced was not true MH. However, her clinical reaction scores were high on the Larach scale and she had symptoms that are not first line in myotonic patients reacting to succinylcholine and inhalation anesthetics.
In our previous study, 16 the substitution p.Arg1679His was found in 1 of 150 healthy anonymized German subjects and p.Lys1393Arg in 1 of 100 Swedish subjects leaving the possibility of rare polymorphisms. However, the population prevalence of a genetic MH disposition has never been studied. Therefore, these control subjects could likewise be as yet unidentified MH carriers. Ideal controls would of course be individuals with known IVCT status not MHS.
After the report by Sei et al. 14 that B lymphocytes also express a functional type 1 RYR, we and others have exploited such a system to investigate the functional effect of candidate mutations linked to MHS and CCD phenotypes. 15,18,20 -22,24 -27 These studies have revealed that most MH-causing mutations disturb normal calcium homeostasis by (1) shifting the sensitivity of pharmacologic RYR1 activation to lower agonist concentrations, and (2) by causing an increase in the resting [Ca 2ϩ ] i . 15, 20, 21, 24 Overall, the results compared well with the IVCT data of the same subjects. Likewise, the results of this study demonstrate a significant alteration of intracellular Ca 2ϩ handling for all 5 candidate mutations and compare well with other studies. 28 Assessing Ca 2ϩ homeostasis in the immortalized B lymphocyte system offers several advantages such as (1) cells can be grown in large numbers, (2) are easy to handle, and (3) can be assayed using a simple methodology such as fluorimetric analysis of cells loaded with the fluorescent Ca 2ϩ indicator fura-2 and stimulated with the RYR1 agonist 4-chloro-m-cresol. In this context, it should be emphasized that this system is only useful for assessing RYR1 mutations and not, for example, mutations found in the ␣-1 subunit gene encoding the DHPR, which has been found to harbor mutations in a small number of MHS families 29 because this isoform of the voltage sensor is probably not expressed in B lymphocytes. Furthermore, it has been estimated that up to 30% of MH families might not link to RYR1 and thus will not benefit from this method. 5, 16 We conclude from our results that the RYR1 amino acid substitutions studied are highly likely to be associated with the MH status in these patients. According to the guidelines of the European Malignant Hyperthermia Group, 30 RYR1 mutations should only be regarded as causative of MH if functional tests have been performed on tissues from at least 2 unrelated individuals carrying the same candidate mutation. This, however, is impeded by the rarity of most RYR1 mutations. We propose our protocol as a complementary approach for the diagnosis of MH-suspected subjects living far away from an MH diagnostic center.
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